Alzheimer's Prevention Study in Genetically Defined High-Risk Patients Includes Roche, Lilly Drugs | GenomeWeb

Researchers at the Washington University School of Medicine have picked two Alzheimer's drugs under development at Roche and Eli Lilly to take through a clinical trial that will test how well these agents prevent the disease in those genetically predisposed to get it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A lack of stability in research funding drives researchers away from academia, researchers write at eLife.

In PLOS this week: canine GWAS of skeletal syndromes, Chagas disease outcomes and genetic ancestry, and more.

A team describes its idea for a clinical trial data-sharing database, called Vivli, ScienceInsider reports.

One case illustrates how DNA evidence can incriminate an innocent person, Scientific American says.